<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572569</url>
  </required_header>
  <id_info>
    <org_study_id>A30127</org_study_id>
    <secondary_id>81Z3100331</secondary_id>
    <nct_id>NCT03572569</nct_id>
  </id_info>
  <brief_title>Risk Stratification in Children and Adolescents With Primary Cardiomyopathy</brief_title>
  <acronym>RIKADA</acronym>
  <official_title>Risk Stratification in Children and Adolescents With Primary Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RIKADA is a prospective study performing systematic family screening including clinical and
      genetic testing in pediatric patients with primary cardiomyopathy and their first-degree
      relatives with the aim to facilitate risk stratification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RIKADA is a long-term prospective study performing in-depth phenotype and genotype
      characterization in children and adolescents with primary cardiomyopathy and their
      first-degree family members. Family screening contains complete cardiac work-up with medical
      history, physical examination, 12-lead-/Holter-electrocardiogram, cardiopulmonary exercise
      testing, echocardiography, cardiovascular magnetic resonance (CMR) and laboratory including
      genetic testing. The aim is to facilitate early identification of at-risk individuals and
      contribute to patient-specific follow-up and therapy regimes preventing progressive heart
      failure and arrhythmia in pediatric CMP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>major cardiovascular events</measure>
    <time_frame>from date of enrollment until the date of death, mechanical circulatory support or heart transplantation, assessed up to 8 years</time_frame>
    <description>death, need for mechanical circulatory support or heart transplantation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Cardiomyopathy</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Left Ventricular Noncompaction</condition>
  <condition>Restrictive Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Index patients</arm_group_label>
    <description>Patients ≤18 years with primary cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First-degree family members</arm_group_label>
    <description>Parents and siblings of index patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA; tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Department of pediatric cardiology including outpatient department
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Index patients:

               -  Age ≤18 years

               -  written informed consent of parents/legal guardians

               -  diagnosis of primary cardiomypathy:

               -  DCM: left ventricular (LV) systolic dysfunction and dilatation greater than two
                  standard deviations (SD) above the mean of a normal population

               -  HCM: LV hypertrophy and septal wall thickness above two SD

               -  RCM: diastolic dysfunction and concordant atrial enlargement

               -  LVNC: separation of the myocardium into a compacted (C) and a non- compacted (NC)
                  layer with an NC/C ratio &gt;2 in echocardiography and/or &gt;2.3 in CMR

               -  ARVC: according to the revised Task Force Criteria

          2. First-degree family members (parents and siblings):

               -  Age ≥3 years

               -  written informed consent of parents/legal guardians and siblings ≥18 years

        Exclusion Criteria:

          -  unwillingness to give consent

          -  myocardial inflammation / myocarditis

          -  systemic disease with cardiac involvement (secondary cardiomyopathy)

          -  structural congenital heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Felix Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine Klaassen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Klaassen, MD</last_name>
    <phone>+49 30 450</phone>
    <phone_ext>540656</phone_ext>
    <email>klaassen@mdc-berlin.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadya Al-Wakeel-Marquard, MD</last_name>
    <phone>+49 30 4593</phone>
    <phone_ext>2883</phone_ext>
    <email>alwakeel@dhzb.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charité - Universitätsmedizin Berlin</last_name>
    </contact>
    <investigator>
      <last_name>Sabine Klaassen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Institute</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Heart Institute</last_name>
    </contact>
    <investigator>
      <last_name>Nadya Al-Wakeel - Marquard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Risk stratification</keyword>
  <keyword>Family screening</keyword>
  <keyword>Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Cardiomyopathy, Restrictive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

